BillionToOne CEO sells EUR 744k while BLLN holds near $150

BillionToOne BillionToOne, Inc. sits in a part of healthcare that still gets paid for execution. Prenatal screening and liquid biopsy oncology are not glamorous businesses in the old biotech sense, but they are the kind of tests that can scale if the assay works, the reimbursement holds and the sales force keeps moving. That is why the stock has been able to trade with the better growth names in healthcare even while the macro backdrop has stayed awkward.

The broader biotech tape has been constructive in 2026. The Nasdaq Biotechnology Index and a fresh crop of IPOs have outperformed, helped by M&A, cancer and obesity innovation, and test adoption that has not cracked under macro pressure. Add a Federal Reserve that has held rates at 3.50% to 3.75% as of late July, with the market now thinking more about hikes later in 2026 than cuts, and you get a setting where profitable or near-profitable growth stories can still command attention. BillionToOne is not alone in that lane, but it is one of the cleaner names in it.

The comparison that matters most here is Natera. Natera trades at a larger scale, with a deeper franchise in noninvasive prenatal testing. Guardant Health is the more obvious oncology peer, and GRAIL sits in multi-cancer early detection. BillionToOne is smaller than Natera, less established in oncology than Guardant, and still building out the second leg of the story. That is the frame you want before you even look at the filing.

InsiderTrades data for the relevant bucket, chief-executive buys at large-cap names, shows a 57.5% 90-day win rate and a 4.98% average return over that horizon. That is historical cohort data, not a forecast for this trade, and it belongs in the comparison because it tells you how this role and size bucket has behaved before, not what BLLN must do next.

The filing: a CEO sale, a plan, and a stock that was already strong

The insider at the center of this is Atay Oguzhan, BillionToOne’s chairman and CEO. The filing covers August 3 trades and was reported August 5 under a Rule 10b5-1 plan adopted March 6, 2026. That matters because the plan removes some of the usual drama from the timing. It does not remove the fact of the sale.

Oguzhan exercised 32,500 options at $2.80 per share and sold 45,000 Class A shares in multiple trades at weighted average prices ranging from $132.50 to $139.50. The euro-normalised filing value on the larger sale was EUR 744,373.67, with a smaller EUR 20,069.93 transaction also reported. The shares sold included stock held by his spouse. The company’s market value in the dossier sits at EUR 5.97 billion, so the larger sale was a small slice of the equity base, but it was still a real sale by the chief executive, not a housekeeping footnote.

The stock closed near $150 on August 5. That is the part that keeps this from being a simple “insider sold into weakness” story. The market had already digested a strong quarter, and the filing landed after the company had put fresh numbers in front of the market. If you are looking for a clean bearish read, this is not it. If you are looking for a CEO who chose to monetize some stock after a sharp move and a strong print, that is exactly what the filing shows.

BillionToOne’s revenue line versus Natera’s scale

BillionToOne reported second-quarter 2026 revenue of $109.4 million on August 5, up sharply year over year, and reiterated full-year 2026 guidance of $450 million to $465 million. That implies 48% to 52% growth over 2025, which is the sort of growth rate that keeps a diagnostics name in the market’s good graces even when the rest of healthcare is trading on caution. The company’s own guidance is doing a lot of the work here. So is the mix of prenatal and oncology tests.

Against Natera, the difference is scale and maturity. Natera is the larger, more established prenatal franchise, and the market knows it. BillionToOne is still the faster-growing name in the comparison set, but it does not yet have the same breadth of commercial history. That is why the stock can trade like a growth story while still being judged like a newer platform. The market is paying for the line of sight, not for a finished business.

That distinction matters when you read a CEO sale. A company with a fast revenue line and a stock near $150 can produce insider selling that looks mechanical rather than ominous. A company with slowing growth and a stretched multiple would be a different case. BillionToOne does not fit that second bucket. Its revenue print and guidance say the business is still expanding at a pace that justifies attention, even if the valuation asks for a lot of execution.

Guardant and GRAIL show the other side of the trade

Guardant Health is the cleaner oncology comparator. It trades on liquid biopsy adoption, test volumes and the long runway for cancer screening and monitoring. GRAIL is the more speculative multi-cancer early detection name, with a different commercial profile and a different kind of market skepticism. BillionToOne sits between those poles. Its prenatal business gives it a more established base, while Northstar keeps the oncology optionality alive.

That mix is why the market can treat BillionToOne as both a diagnostics growth story and a platform story. The company’s single-molecule counting technology is the core pitch, but the real question is whether it can keep converting that technology into durable test volume. The Q2 print says yes, for now. The guidance says management thinks the path is still open. The insider sale says the CEO was willing to take some money off the table after the stock had already moved.

There is no need to force a grander conclusion than that. Guardant and GRAIL are useful because they remind you how different the oncology leg can look depending on the stage of the business. BillionToOne is not being valued like a pure oncology moonshot. It is being valued like a company that has already shown commercial traction and still has room to scale. That is a better place to be, but it also leaves less room for error.

What our data says about CEO trades in this bucket

InsiderTrades data puts this filing in a bucket that has historically been decent, not magical. The chief-executive buys at large-cap names cohort has a 57.5% 90-day win rate and a 4.98% average return over 90 days. The 365-day average return in that same bucket is 42.02%. Those are historical cohort figures, and they are useful only if you keep them in their lane. They do not tell you what BLLN will do after this filing. They tell you that chief executive activity in larger names has not been random noise in our sample.

The score rationale in our data is straightforward enough. The filing came from a chief executive, it sat inside an insider cluster, and the euro-normalised value was small relative to the company’s market value. That combination keeps the signal from becoming a panic trade. It also keeps it from being dismissed as trivial. A CEO sale after a strong quarter is not the same thing as a distressed insider exit, and the market usually knows the difference before the headline writers do.

The cluster detail needs a careful read. Our dossier marks this as a cluster, but the recent declarations all point back to Oguzhan. In other words, this is not a broad board-level selling wave. It is one executive filing multiple transactions around the same date. That is still worth reading, because the chief executive is the person whose actions the market tends to notice first. It is also why you should not overstate the breadth of the selling.

The valuation question is the real one, not the filing alone

BillionToOne’s market cap in the dossier is EUR 5.97 billion. That is not a tiny diagnostics company anymore, and it changes the way you read the filing. A EUR 744,373.67 sale is not nothing, but it is not the kind of number that rewrites the equity story on its own. The market is still looking at revenue growth, margin path and whether the company can keep expanding its prenatal lead while oncology matures.

That is where the comparison with Natera helps again. Natera has already earned a larger market footprint because it has a more established commercial engine. BillionToOne is still in the phase where each quarter has to prove the platform can keep compounding. The stock near $150 suggests the market is willing to pay for that proof. The CEO sale suggests management is also willing to monetize some of that proof when the window opens.

Our fundamental screen is not a thesis by itself, but it does frame the debate. BillionToOne’s fundamental score is 42, with a quality score of 47 and a value score of 36. That is a middling read, not a screaming bargain and not a broken story. In plain English, the company has enough growth to stay interesting, but the valuation and quality mix do not hand you an easy answer. You still have to do the work.

What to watch after the August 5 filing

The next real test is not the filing itself. It is whether the company can keep turning the Q2 print into repeatable operating momentum. Revenue growth of $109.4 million in the quarter and full-year guidance of $450 million to $465 million set the bar. If the next update shows the same kind of traction, the CEO sale will look more like a liquidity event inside a strong trend than a warning flare.

Watch the prenatal business first, because that is still the anchor. Then watch Northstar, because oncology is where the optionality lives. If the company keeps widening the gap between its own growth rate and the more established peers, the market will keep giving it room. If growth slows while the stock stays elevated, the same filing will look more expensive in hindsight.

The insider piece is useful because it tells you what one of the most informed holders chose to do after a strong quarter and a stock near $150. It does not tell you whether the next leg higher comes quickly or whether the market pauses to digest the move. It does tell you that the CEO was happy to sell into strength while the company was still printing growth and the sector was still in favor. That is the setup to watch into the next earnings date and the next Form 4.

This is not investment advice.